Fmr LLC Sells 503,609 Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)

Fusion Pharmaceuticals Inc. NASDAQFUSN is a biopharmaceutical company that specializes in developing and commercializing targeted therapies for cancer. The company's lead product candidate is pemigatinib, an oral tyrosine kinase inhibitor that is currently being studied in clinical trials for the treatment of various types of cancer.

Fmr LLC is a private investment firm that was founded in 2013 and has been actively investing in the biopharmaceutical industry. The company's portfolio includes investments in several other public and private companies, including Fusion Pharmaceuticals Inc. NASDAQFUSN.

In the third quarter of 2021, Fmr LLC sold 503,609 shares of Fusion Pharmaceuticals Inc. NASDAQFUSN, reducing its holdings in the company by approximately 10.8%. After the sale, Fmr LLC owned approximately 4,177,848 shares of the company's stock, which represented approximately 5.77% of the outstanding shares of Fusion Pharmaceuticals Inc. NASDAQFUSN.

It is worth noting that the sale of shares by Fmr LLC does not necessarily indicate any negative sentiment towards the company or its prospects. Rather, it may reflect the investment firm's decision to diversify its portfolio or realize a profit on its investment in Fusion Pharmaceuticals Inc. NASDAQFUSN.